BlackRock, Inc. 13D and 13G filings for Cytek Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-18 2:52 pm Sale | 2025-06-30 | 13G | CYTEK BIOSCIENCES INC CTKB | BlackRock Inc. BLK | 16,531,858 13.100% | -1,950,937 (-10.56%) | Filing |
| 2025-02-05 1:23 pm Purchase | 2024-12-31 | 13G | CYTEK BIOSCIENCES INC CTKB | BlackRock Inc. BLK | 18,482,795 14.300% | 703,042 (+3.95%) | Filing |
| 2024-01-23 4:13 pm Purchase | 2023-12-31 | 13G | CYTEK BIOSCIENCES INC CTKB | BlackRock Inc. BLK | 17,779,753 13.100% | 2,944,538 (+19.85%) | Filing |
| 2023-05-05 11:52 am Purchase | 2023-04-30 | 13G | CYTEK BIOSCIENCES INC CTKB | BlackRock Inc. BLK | 14,835,215 10.900% | 6,467,608 (+77.29%) | Filing |
| 2023-02-03 12:10 pm Purchase | 2022-12-31 | 13G | CYTEK BIOSCIENCES INC CTKB | BlackRock Inc. BLK | 8,367,607 6.200% | 8,367,607 (New Position) | Filing |